Business
VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering
About this update from Vyne Therapeutics Inc.
[{"type":"text","content":"Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced it will host a virtual R&D Day event on Thursday, November 9, 2023 at 1:30 p.m. ET. To register, click here. The event will feature a presentation from Dr. Amit Pandya, former President of the Global Vitiligo Foundation. VYNE management will discuss the final results from the Phase 1b trial for VYN201 in patients with nonsegmental vitiligo. In addition, VYNE management will review the preclinical data for its oral BD2-selective BET inhibitor, VYN202, in psoriasis and rheumatoid arthritis and discuss its development plans for both programs. A live question and answer session will follow the formal presentation. About Dr. Amit Pandya Dr. Amit Pandya recently served as President of the Global Vitiligo Foundation and is currently Staff Dermatologist, Department of Dermatology, Palo Alto Foundation Medical Group. Dr. Pandya’s practice focuses on patients with vitiligo, melasma, post-inflammatory hyperpigmentation and other pigmentary disorders. His professional interests also include: pigmentary disorders, including vitiligo, melasma, post-inflammatory hyperpigmentation, erythema dyschromicum perstans, lichen planus pigmentosus and Riehl’s melanosis; vitiligo surgery, including mini-punch grafting, suction blister epidermal grafting, non-cultured epidermal suspension grafting, and melanocyte-keratinocyte transplantation procedure. Dr. Pandya has given hundreds of lectures nationally and internationally, and has published over 200 research articles and book chapters, mostly on pigmentary disorders. He is also working with several organizations, foundations and companies to discover and test new treatments for these disorders. About VYN201 VYN201 is a pan-bromodomain BET inhibitor designed to be locally-administered as a “soft” drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low s...